194 related articles for article (PubMed ID: 9869569)
21. The efficacy of trovafloxacin versus ceftriaxone in the treatment of experimental brain abscess/cerebritis in the rat.
Nathan BR; Scheld WM
Life Sci; 2003 Aug; 73(14):1773-82. PubMed ID: 12888116
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of trovafloxacin, a new quinolone antibiotic, in experimental staphylococcal endocarditis due to oxacillin-resistant strains.
Bayer AS; Li C; Ing M
Antimicrob Agents Chemother; 1998 Jul; 42(7):1837-41. PubMed ID: 9661030
[TBL] [Abstract][Full Text] [Related]
23. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
[TBL] [Abstract][Full Text] [Related]
24. In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains.
Frosco MB; Melton JL; Stewart FP; Kulwich BA; Licata L; Barrett JF
Antimicrob Agents Chemother; 1996 Nov; 40(11):2529-34. PubMed ID: 8913458
[TBL] [Abstract][Full Text] [Related]
25. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci.
Entenza JM; Blatter M; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1994 Dec; 38(12):2683-8. PubMed ID: 7695248
[TBL] [Abstract][Full Text] [Related]
26. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
27. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP
Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895
[TBL] [Abstract][Full Text] [Related]
28. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
[TBL] [Abstract][Full Text] [Related]
30. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
[TBL] [Abstract][Full Text] [Related]
31. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
Dalhoff A; Schubert S
Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
[TBL] [Abstract][Full Text] [Related]
32. Treatment of experimental bacterial keratitis with topical trovafloxacin.
Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.
Dubin DT; Fitzgibbon JE; Nahvi MD; John JF
Antimicrob Agents Chemother; 1999 Jul; 43(7):1631-7. PubMed ID: 10390214
[TBL] [Abstract][Full Text] [Related]
34. Trovafloxacin.
Haria M; Lamb HM
Drugs; 1997 Sep; 54(3):435-45; discussion 446. PubMed ID: 9279505
[TBL] [Abstract][Full Text] [Related]
35. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
Girard AE; Girard D; Gootz TD; Faiella JA; Cimochowski CR
Antimicrob Agents Chemother; 1995 Oct; 39(10):2210-6. PubMed ID: 8619569
[TBL] [Abstract][Full Text] [Related]
36. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
[TBL] [Abstract][Full Text] [Related]
37. Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae.
López Fornas F; Martínez García F; Pérez Salmeron J; Roldán Conesa D; Cortés Sanchez R; García Alberola A; Ruíz Gómez J; Gómez Gómez J; Valdés Chávarri M
J Antimicrob Chemother; 2001 May; 47(5):623-9. PubMed ID: 11328774
[TBL] [Abstract][Full Text] [Related]
38. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
[TBL] [Abstract][Full Text] [Related]
39. Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.
Hershberger E; Coyle EA; Kaatz GW; Zervos MJ; Rybak MJ
Antimicrob Agents Chemother; 2000 Jul; 44(7):1921-4. PubMed ID: 10858355
[TBL] [Abstract][Full Text] [Related]
40. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
